JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Fulgent Genetics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

23.6 0.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23

Max

23.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.4M

-19M

Pardavimai

8.3M

82M

Pelno marža

-23.539

Darbuotojai

1,313

EBITDA

-3.5M

-15M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+7.79% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

181M

730M

Ankstesnė atidarymo kaina

22.96

Ankstesnė uždarymo kaina

23.6

Naujienos nuotaikos

By Acuity

50%

50%

163 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Fulgent Genetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-23 23:51; UTC

Rinkos pokalbiai

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025-10-23 23:37; UTC

Rinkos pokalbiai

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025-10-23 22:58; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-10-23 22:57; UTC

Rinkos pokalbiai

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -2-

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025-10-23 22:17; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025-10-23 21:41; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025-10-23 21:05; UTC

Uždarbis

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-23 20:35; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025-10-23 20:28; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025-10-23 20:15; UTC

Rinkos pokalbiai
Uždarbis

Global Commodities Roundup: Market Talk

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Adj EPS $1.71

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Sales $5.52B

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q EPS $1.67

2025-10-23 20:09; UTC

Uždarbis

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025-10-23 20:07; UTC

Uždarbis

Blackstone Looks to IPOs for Investment Exits -- Update

2025-10-23 20:05; UTC

Uždarbis

Intel 3Q Gross Margin 38.2% >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025-10-23 20:04; UTC

Uždarbis

Intel: 4Q Guidance Excludes Altera >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Sees 4Q Adj EPS 8c >INTC

Akcijų palyginimas

Kainos pokytis

Fulgent Genetics Inc Prognozė

Kainos tikslas

By TipRanks

7.79% į viršų

12 mėnesių prognozė

Vidutinis 25.33 USD  7.79%

Aukščiausias 30 USD

Žemiausias 21 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fulgent Genetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

17.32 / 19.04Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

163 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat